CAMBRIDGE, Mass.--(BUSINESS WIRE)--
RaNA Therapeutics, a leader in the discovery and development of a new
class of medicines that target RNA to selectively activate protein
expression within the body's own cells, today announced the successful
completion of a $55 million oversubscribed Series B financing. Proceeds
from the financing will be used to bolster RaNA's proprietary platforms
focused on epigenetic gene upregulation and messenger RNA (mRNA)
stabilization, including investments in chemistry and oligonucleotide
synthesis capabilities. In addition, the financing will support
preclinical efforts towards lead optimization and IND-enabling studies
for the company's priority programs that focus on the treatment of
spinal muscular atrophy and Friedreich's ataxia. RaNA anticipates having
up to two novel therapies in the clinic in 2017.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in